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 Abstract 
Aberrant hyperactivation of the phosphatidylinositol 3-kinase (PI3K) cell-
signaling pathway, one of the most prominent cell growth, proliferation and 
survival pathways in the human body, has been observed in many forms of 
cancer. Upon deregulation, this pathway can facilitate the evasion of programmed 
cell death, the stimulation of autonomous growth, and the evasion of regular 
growth-inhibitory signals. While it was initially believed that the 
dephosphorylation activity of lipid phosphatases served to counteract the pathway 
by hydrolyzing phosphatidylinositol(3,4,5)trisphosphate (PtdIns(3,4,5)P3) to 
phosphatidylinositol(4,5)bisphosphate (PtdIns(4,5)P2), emerging evidence 
suggests that SH2-domain containing inositol 5’ phosphatase 1 and 2 (SHIP1/2) 
may in fact facilitate, rather than suppress, oncogenesis in certain contexts. We 
hypothesize, therefore, that chemical inhibition of SHIP would decrease 
phosphatidylinositol bisphosphate levels, thus reducing downstream activation of 
cell survival and proliferation effectors. Previous work in the Kerr lab identified a 
SHIP1 selective inhibitor (3AC) that was capable of killing malignant 
hematological cells but was ineffective against other, non-hematological 
malignancies. Therefore, this study sought to identify further, more effective 
inhibitors, particularly those capable of targeting both SHIP1 and SHIP2, as well 
as to investigate the overall effect such pan-SHIP inhibition has on blood and 
breast cancers. In this study, we identify several lead pan-SHIP inhibitors capable 
of preventing the hydrolysis of PtdIns(3,4,5)P3 to PtsIns(3,4)P2. Furthermore, we 
demonstrate the ability of these pan-SHIP inhibitors to reduce cell viability and to 
effectively kill leukemia, multiple myeloma, and breast cancer cells. In 
conclusion, this study suggests that the inhibition of SHIP1 and SHIP2 may hold 
great clinical promise as a novel therapeutic approach in the treatment of many 
different cancers.  
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 Introduction 
 
The phosphotidylinositol 3-kinase (PI3K) pathway, a prominent cell 
growth and proliferation signal transduction system, is perhaps the most 
commonly activated signaling pathway in human cancers (Liu et al., 2009). The 
phosphatidylinositol 3-kinase pathway is activated upon the binding of an 
epidermal growth factor to a membrane-bound receptor tyrosine kinase. This 
binding induces dimerization of the receptor monomers, which are subsequently 
autophosphorylated. These phosphorylated monomers serve as binding and 
activation sites for PI3-kinases, whose primary biochemical function is to 
phosphorylate inositol phospholipids in the plasma membrane. Specifically, these 
activated PI3-kinases migrate along the cytosolic side of the cellular membrane 
and bind to phosphatidylinositol(4,5)bisphosphate (PtdIns(4,5)P2), adding a 
phosphate group to its inositol ring at the 3’ position. This results in the formation 
of second messenger, phosphatidylinositol(3,4,5)trisphosphate (PtdIns(3,4,5)P3, 
or “PIP3”), which, by acting as a docking site, further activates the 
serine/threonine kinase, Akt (also known as protein kinase B, or PKB) (Alberts et 
al., 2010).  
Activated Akt has many different substrates, and hence, can result in a 
multitude of effects. Several of the most notable include inhibition of apoptosis, 
evasion of regular growth-inhibitory signals, and the autonomous stimulation of 
cellular proliferation. Consistent with these effects, many tumors, including both 
hematopoietic and tissue malignancies, present with constitutive activation of the 
2 
PI3K-Akt pathway (Fuhler et al., 2012). Therefore, targeting this signal 
transduction system with specific inhibitors may have broad clinical application in 
the treatment of multiple cancers (Bunney and Katan, 2010; Harvey and Lonial, 
2007).  
Common belief maintains that PI3K signaling is naturally counteracted by 
the dephosphorylation activity of lipid phosphatases. Phosphatase and tensin 
homolog, PTEN, hydrolyzes phosphatidylinositol(3,4,5)trisphosphate to 
phosphatidylinositol(4,5)bisphosphate by removing the phosphate group at the 3’ 
position of the inositol ring (see figure 1). This hydrolysis reduces the activation 
of the proto-oncoprotein, Akt, and its downstream effectors promoting cell growth 
and survival. As such, PTEN functions as a potent tumor suppressor (Ruela-de-
Sousa et al., 2010). The other class of lipid phosphatase implicated in the PI3K 
pathway, SH2-domain containing inositol 5’ phosphatase (SHIP), also hydrolyzes 
PIP3 to PIP2, but does so by removing the phosphate group at the 5’ position of 
the inositol ring (i.e. taking PtdIns(3,4,5)P3 to PtdIns(3,4)P2; see figure 1) (Kerr, 
2011). Based on the well-characterized tumor suppressing action of PTEN, it has 
generally been assumed that the intracellular enzymatic activity of SHIP functions 
to counteract the PI3K-Akt pathway as well. However, several intriguing 
observations and a growing body of literature are beginning to challenge this 
view. 
While a loss of PTEN has been proven to confer increased susceptibility to 
cancer development, a loss of SHIP has not been demonstrated to have the same 
effect (Kerr, 2011). Based on recent study, it seems that PtdIns(3,4)P2 actually 
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binds the PH domain of Akt more effectively than does PtdIns(3,4,5)P3 (Ma et al., 
2008), hence serving to enhance Akt activation (Sheid et al., 2002), contrary to 
PTEN. These findings are further supported by notably increased PtdIns(3,4)P2 
levels observed in malignant leukemia cells (Constantini, 2009; Brooks et al., 
2010).  
Given that the potent Akt-activating potential of PtdIns(3,4)P2 is directly 
facilitated by SHIP, we hypothesize that chemical inhibition of SH2-domain 
containing inositol 5’ phosphatase would decrease intracellular PtdIns(3,4)P2 
levels, thus reducing the activation of downstream effectors of cell survival and 
proliferation. As a result, this study sought to identify compounds capable of 
inhibiting both paralogs of SHIP: SHIP1 and SHIP2. Their 38% sequence 
homology (Fuhler et al., 2012) suggests that these two copies of the gene evolved 
from a common ancestral gene, but now carry out slightly different functions 
within the body. SHIP1 expression seems to be restricted to cells from the 
hematopoietic lineage and osteolineage (blood and bone marrow-forming cells, 
respectively), whereas SHIP2 seems to be ubiquitously expressed in all cells 
(Hazen et al., 2009, Rohrschneider et al., 2000).  Previous work in the Kerr lab 
identified a SHIP1 selective inhibitor, 3 α-aminocholestane (3AC), that 
effectively killed multiple myeloma cells in vivo; however, this compound was 
relatively insoluble and was largely ineffective against non-hematological 
cancers. Via high throughput screening strategies, this study identified several 
lead pan-SHIP inhibitors that circumvented the challenges associated with 3AC 
4 
and demonstrated great promise as novel therapeutic agents in the treatment of 
breast and hematopoietic cancers. 
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Materials and Methods 
  
Potential Inhibitors 
All potential SHIP1/2 inhibitory compounds were synthesized in the organic 
chemistry laboratory of Dr. John D. Chisholm at Syracuse University, in 
Syracuse, NY. Compounds were derivatives of known SHIP inhibitors belonging 
to one of three groups: aminosteroids, tryptamines, or quinolones based on 
chemical structure. In total, more than 100 compounds were synthesized and 
screened at varying concentrations. Compounds were stored in solid state at  
-20°C until ready for use, at which time working stocks of a given concentration 
were made according to molecular weight and solubility, as provided by Dr. 
Chisholm and lab. 
 
SHIP1 
Expression and purification of human recombinant SHIP1 was performed 
according to a protocol previously established in the Kerr laboratory. A SHIP1 
cDNA expression construct was amplified by PCR from the pMIGR1 (SHIP1) 
vector (Tu et al., 2001) and was then inserted into the pET24b bacterial 
expression vector at the EcoR1 and Xho1 restriction sites (see figure 2). This 
specific insertion created a SHIP1-His tag fusion at the C terminus. The His-
tagged SHIP1 was then expressed in Escherichia coli Rosetta Gami 2 (DE3) pLys 
cells by induction after the addition of 0.5mM IPTG to trigger transcription. 
Lastly, SHIP1 was purified using Ni-chelating bead chromatography (Brooks et 
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al., 2010). To avoid the effects of repeated freeze/thaw cycles, SHIP1 protein 
stock was aliquoted and stored at -20 °C for use within 2 months and at -80 °C for 
use up to 6 months. It was found that stocks stored at -80°C maintained 
significantly greater enzymatic activity, and therefore, all but stocks currently in 
use were stored at -80°C. 
 
SHIP2 
While members of the Kerr lab worked to finalize a human SHIP2 protein 
purification protocol to be performed in the lab (like that which they have 
established for human SHIP1) SHIP2 Lipid Phosphatase, active (E-1000) was 
obtained from Echelon Biosciences, Inc. (Salt Lake City, UT). This N-terminal, 
His-tagged recombinant human SHIP2 (a truncated form containing SH2 domain 
and inositol 5-phosphatase catalytic domain) was also purified from E. coli using 
nickel column chromatography. This protein stock had approximately twice the 
enzymatic activity of the SHIP1 protein stock purified in-house and therefore, was 
used at half the concentration throughout all assays. To avoid the effects of 
repeated freeze/thaw cycles, SHIP2 protein stock was aliquoted and stored at  
-20°C for use within two months and at -80°C for use up to six months. 
 
PIP3 
D-myo-Phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) was obtained 
from Echelon Biosciences, Inc. (Salt Lake City, UT), and served as SHIP1/2’s 
substrate in all assays. As per manufacturer’s instructions, 1mg PIP3 (P-3908) was 
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reconstituted in 1020µl ddH2O. Reconstituted PIP3 was aliquoted and stored at -
20°C for up to three months. PIP3 was used at concentration of 1mM in all assays. 
 
Malachite Green Assay to determine SHIP1/2 enzymatic activity 
To determine the enzymatic activity of SHIP in vitro, Malachite Green Solution 
(K-1501) was obtained from Echelon Biosciences, Inc. and was stored at 4°C, 
away from light, for use within six months. Through the course of this project we 
found the shelf life of Echelon’s Malachite Green Solution to be shorter than 
manufacturer’s suggestion, and used solutions within three to four months. 
Malachite Green Phosphatase Detection Assay was conducted as previously 
described (Brooks et al., 2010) in accordance with the manufacturer’s protocol. In 
this assay, SHIP1/2 was mixed with substrate PtdIns(3,4,5)P3 in the presence of 
potential inhibitor in 96-well plates. Inhibitors were dissolved in respective 
solvents and tested at final concentrations of 1mM, 500µM, 250µM, and 125µM, 
respectively (see figure 3). SHIP1 was prepared using ratio of 15µl SHIP1:285µl 
buffer, and SHIP2 was prepared using ratio of 7.5µl SHIP2:292.5µl buffer. Buffer 
solution consisted of 50mM HEPES pH 7.4, 100mM NaCl, 1mM MgCl2, and 
0.25mM EDTA. 10µl of potential inhibitor was then mixed with 90µl of 
SHIP/buffer solution. 3µl PIP3 (1mM) was added to each well, followed by 22µl 
of inhibitor/SHIP/Buffer solution. Each reaction was tested in triplicate. The 96-
well plate was then incubated at 37°C for 20 minutes. After incubation, 100µl of 
Malachite Green Solution was introduced to each reaction, which were then 
allowed to react in the dark for 20 minutes. Final results were quantified via Gen5 
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plate reader at absorbance of 620nm. The darker the color/higher the reading, the 
more inorganic phosphate has been liberated (see figure 3), hence indicating a 
higher activity of SHIP. 
 
Cell lines studied, obtained from American Type Culture Collection (ATCC) 
(Manassas, VA) 
K562: 53-year old female, chronic myelogenous leukemia (CML), NB4: 23-year 
old female, acute premyelocytic leukemia (APL), HSB2: 11.5-year old white 
male, acute lymphoblastic leukemia (ALL), 697: 12-year old male, acute 
lymphocytic leukemia (ALL), OPM-2: 56-year old female, myeloma relapse, 
MCF-7: 69-year old Caucasian female, breast cancer, MDA MB 231: 51-year old 
Caucasian female, breast cancer.  
K562, NB4, HSB2, and 697 leukemia cells, as well as OPM-2 multiple 
myeloma cells, were routinely maintained in Iscove’s Modified Dulbecco’s 
Medium (IMDM) (ATCC) supplemented with 10% fetal bovine serum 
(Mediatech, Manassas, VA, USA), whereas MDA-MB-231 and MCF-7 breast 
cancer cells were cultured in Eagle’s minimal essential medium (EMEM) with 
10% fetal calf serum and L-glutamine. 
 
Dojindo Cell Counting Kit-8 (CCK8)-Cell Viability/Cytotoxicity Assay 
Cell viability was determined with Cell Counting Kit-8 from Dojindo as per 
manufacturers’ instructions (Dojindo Molecular Technologies, Rockville, MD). 
Cells were treated in triplicate for 46 hours at 37°C with increasing concentrations 
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of inhibitory compounds or vehicle (5,000 cells/well, 10µl inhibitor/well). 
Dojindo CCK-8 solution was added (10µl/well) and cells were allowed to 
incubate at 37°C for another 2 hours. During this time, Dojindo’s highly water 
soluble tetrazolium salt, WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] forms a water-soluble 
formazan dye upon reduction in the presence of an electron mediator. The 
solution changes from colorless to orange upon the production of formazan dye, 
and therefore, stronger color corresponds to greater cell viability. This 
colorimetric assay is also quantified via the Gen5 plate reader program at an 
absorbance of 450nm. The optical density (OD) of compound-treated cells was 
divided by the OD of their vehicle control, and the viability was expressed as a 
percentage of untreated cells. Results are expressed as mean ± standard error of 
the mean (SEM) of three individual experiments (Fuhler et al., 2012). 
 
In vivo toxicity and tumor challenge studies 
Prior to challenging mice with malignancies and subsequently treating them with 
inhibitors, we first ran toxicity screens of our lead compounds in wildtype 
C57Bl/6 mice (The Jackson Laboratory, Bar Harbor, ME). This step is crucial in 
determining the ultimate effect of SHIP1/2 inhibition; for example, should we 
challenge mice with tumor cells, treat them, and the mice die, how do we know if 
it was the cancer that killed them or toxicity of the compound? These initial 
toxicity screens provide insight into how well each inhibitor is tolerated by a 
living organism. Dosages were dependent upon the particular compound, and 
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were administered at several different concentrations per inhibitor. These dosages 
ranged from 7.63mg/kg (compound K103) to 28.9mg/kg (compound K102).  
Upon completion of toxicity screening, NOD/SCID/γcIL2R (NSG) mice 
(The Jackson Laboratory, Bar Harbor, ME) were challenged with 1 × 107 OPM2 
cells via intraperitoneal (IP) injection. T cells and B cells of the adaptive immune 
system are impaired in these models and therefore, any decrease in tumorigenesis 
can de attributed directly to the compounds administered. “Treatment” began 6 
hours post IP injection with either compound or vehicle. In our initial study, 3AC 
was suspended in a 0.3% Klucel/H2O solution at 11.46 mM and administered via 
200µl IP injection. Vehicle-treated mice received 200µL injection of 0.3% 
Klucel/H2O solution. The final concentration of 3AC in the treated mice was 60 
µM. The mice were then treated with 3AC or vehicle daily for the next 6 days and 
then twice per week in the remaining 15 wks of the survival study. Effects were 
analyzed via direct observation and measurement, via IVIS imaging (a 
visualization method utilizing luciferase bioluminescence), via Hemavet 950S 
automated blood cell analyzer, and via flow cytometry (a laser-based, biophysical 
technology useful for cell counting, sorting, and biomarker detection). Lead pan-
SHIP inhibitors identified throughout the course of this study are currently being 
tested at 5-15mg/kg in 5% DMSO:Saline, 5% DMSO:H2O, or in 100% H2O, 
depending upon their solubility. 
All in vivo studies were performed with approval from the Committee on 
the Humane use of Animals (CHUA) at SUNY Upstate Medical University. 
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Results 
 
 
High-throughput screening identifies novel pan-SHIP inhibitors 
To date, the three-dimensional molecular structure of SHIP is not known, and 
therefore, designing a particular inhibitor to “fit” and block the SHIP molecule’s 
activity is not feasible. Therefore, a high throughput screening method was 
adopted such that a multitude of derivatives of known SHIP1/2 inhibitors could 
rapidly be analyzed for their ability to prevent the hydrolysis of PtdIns(3,4,5)P3 to 
PtdIns(3,4)P2 in vitro. The colorimetric Malachite Green Assay allows for easy 
visualization of phosphate release, indicative of phosphatase (in our case, SHIP) 
activity. Upon dephosphorylation by SHIP at the 5’ position, a free inorganic 
phosphate group is released into the solution, which reacts to form a colored 
complex with molybdate/malachite green. This color is then quantified by reading 
the absorbance at 620 nm. In other words, the stronger the color, the more potent 
the activity of SHIP. In this particular assay, we hoped to see little to no color 
change of the Malachite Green Solution. A colorless result (or one with a very 
low OD) indicates that SHIP has been inhibited, keeping PIP in the 
PtdIns(3,4,5)P3 form, as desired. Throughout the course of this study, 
approximately 1/3 of the 100+ compounds screened were determined to inhibit 
the dephosphorylation activity of SHIP1 and/or SHIP2 at 1mM. These top “hits” 
were then tested against SHIP1 and SHIP2 at lower concentrations, specifically at 
500µM, 250µM, and 125µM. After testing each compound at each concentration 
in triplicate, in three separate experiments, several compounds emerged as “lead 
inhibitors,” capable of blocking the activity of both SHIP1 and SHIP2 better than 
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the parent compounds from which all new inhibitors were derived (see figure 4). 
The lead pan-SHIP inhibitors that we moved forward with in our study included 
four aminosteroids: K118, K141, K142, K179, and one tryptamine: K149, based 
on percent inhibition and solubility.   
 
Pan-SHIP inhibition reduces the viability of blood and breast cancer cells ex-
vivo  
Upon identifying the most potent pan-SHIP inhibitors in vitro using the 
Malachite Green Assay, we then wanted to test the ability of these compounds to 
kill live cancer cells of both the hematopoietic and non-hematopoietic domains.  
Previous work in the Kerr lab demonstrated the ability of SHIP1-selective 
inhibitor 3AC to reduce the viability of malignant hematopoietic cells (OPM2 
cells-multiple myeloma) in vitro and in vivo (Brooks et al., 2010). However, 
because SHIP1 expression is restricted to the hematopoietic compartment, the 
potential clinical applicability of 3AC is likewise restricted, feasible only in the 
treatment of blood cancers. By also targeting SHIP2, which is ubiquitously 
expressed in cells throughout the body, it was our hope that lead pan-SHIP 
inhibitors would demonstrate the ability to target and kill a broader range of 
malignancies.  
As shown in figure 5, the parent pan-SHIP inhibitors from which our new 
compounds have been derived (3AC, 1PIE, 2PIQ, 6PTQ) demonstrate notable 
killing potential against OPM2 multiple myeloma cells, as well as against MDA-
MB-231 and MCF-7 breast cancer cells. Consistent with its selectivity, 3AC was 
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found to lack any killing activity in the latter two, as neither breast cancer cell line 
expresses SHIP1.  
Of greater significance, the lead pan-SHIP inhibiting derivatives 
themselves (K118, K141, K142, K149, K179) demonstrate even more potent cell-
killing potential than their parent compounds (see figures 6-7). In nearly all 
experiments against leukemia and breast cancer cells, aminosteroid derivative 
K118 exhibits more notable cell killing than not only parent compound 3AC, but 
all other aminosteroid derivatives as well (see figure 6). Even at concentrations as 
low as 5µM, less than 35% of 697 cells survived; when looking at the NB4 cell 
line, K118 killed approximately 85% cells at a slightly increased concentration of 
12.5µM. Furthermore, it is important to note that this compound is water soluble, 
making its potential even more exciting, especially from a pharmacological/ 
clinical perspective. The lead tryptamine derivative, K149, demonstrated more 
potent cell killing ability than its parent (K103) and all other derivatives, against 
every cell line, at nearly every concentration (see figure 7). Overall, 3AC 
(aminosteroid) derivatives were more effective than 2PIQ (tryptamine) derivatives 
(compare figures 6 and 7), and as may be expected, hematopoietic cancer cells 
expressing both SHIP1 and SHIP2 showed a higher sensitivity to pan-SHIP 
inhibitors than they did to 3AC which is selective only for SHIP1. 
 
Inhibition of SHIP combats tumorigenesis in vivo 
 
 While the lead pan-SHIP inhibitors identified through this study are just 
starting to be introduced to in vivo models, the effects of their parent compounds 
(3AC, 2PIQ) have been well-characterized for comparison in this study. Dosages 
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were adjusted based on each particular compound, but for the initial toxicity 
screens, 3AC (also identified as K100) was administered and well-tolerated at 25-
26.5mg/kg, 2PIQ (also identified as K103) was administered and well-tolerated at 
7.63mg/kg and 15.25mg/kg, but proved toxic at 22.88mg/kg (resulted in death). 
Upon determining the maximum therapeutic dose in these otherwise healthy 
C57Bl/6 mice, SCID mice, lacking the T cells and B cells of their adaptive 
immune system, were challenged with multiple myeloma cells via intraperitoneal 
injection then treated with the predetermined dosage of inhibitory compound (or 
vehicle) six hours later (25mg/kg for 3AC, 12.5mg/kg for 2PIQ, and 0.3% 
Klucel/H2O or 50% DMSO/PBS for vehicle). Mice were then injected daily for 
one week (known as the induction phase) followed by biweekly injections of 
3AC, 2PIQ, or vehicle for the remaining 15 weeks of the study (known as the 
maintenance phase). In the mice treated with 2PIQ, we saw an increase in 
neutrophils and myeloid derived suppressor cells, MDSCs, (consistent with our 
findings from the initial toxicity study) (see figure 8), which helped to combat 
tumorigenesis. However, 2PIQ was not well-tolerated by the hosts and many died 
within the first several weeks of the study. Treatment with 3AC did not confer 
such toxic effects and notably reduced the viability of multiple myeloma cells in 
vivo. 100% of vehicle-treated mice (those not receiving any inhibitory compound) 
developed significant tumor growth, while only 40% of 3AC-treated mice showed 
any tumor growth whatsoever, many of which were minor (see figure 9). Most 
importantly, we found that treatment with 3AC results in significantly enhanced 
survival of mice post-multiple myeloma challenge (see figure 10).  At the 
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culmination of the tumor challenge study, more than twice the number of 3AC-
treated mice survived than vehicle-treated mice. Again, it is important to 
remember that 3AC is SHIP1 selective, and therefore, shall only confer results of 
this nature to cancers of the blood and bone marrow. Hoping to expand the 
clinical applicability of SHIP inhibition, we are currently beginning the same in 
vivo trials with the lead pan-SHIP inhibitors identified thus far in the study, K118, 
K141, K142, K149, K179. K118, K141, K142, and K179 are all derivatives of 
3AC and hopefully will be tolerated as well, while K149 is a derivative of 2PIQ, 
raising some concern regarding toxicity. These lead pan-SHIP inhibitors are 
currently being tested at 5-15mg/kg in 5% DMSO:Saline, 5% DMSO:H2O, or in 
100% H2O, depending upon their solubility. 
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Discussion 
 
 The prevalent belief that PI3K signaling is counteracted by all lipid 
phosphatases (Hamilton et al., 2011) is slowly being challenged (Kerr, 2011; 
Fuhler et al., 2011). It has recently been shown that the hydrolysis of 
PtdIns(3,4,5)P3 to PtdIns(3,4)P2 actually results in more efficient binding of Akt 
(Franke et al., 1997), hence enhancing cell proliferation and survival effects.  
Given the implication of the PI3K-Akt pathway in many different malignancies, 
targeting its intricate components, such as SH2-domain containing inositol 5’ 
phosphatase, presents both an opportunity and a challenge for novel cancer 
therapies. Because SHIP directly facilitates formation of the PtdIns(3,4)P2 
product, researchers are now seeking ways to inhibit its intracellular enzymatic 
activity. By decreasing PtdIns(3,4)P2 levels, it has been hypothesized that growth, 
division, and survival signals will be decreased as well (Artemenko, 2009), 
ultimately resulting in increased cell death. Targeting this phosphatase in cancer 
treatment can be complicated by the existence its two paralogs; SHIP1 seems to 
be expressed predominately in the hematopoietic compartment, while SHIP2 
appears to be ubiquitously expressed. While previous work in the Kerr lab 
identified the ability of a SHIP1 selective inhibitor to reduce viability of 
malignant hematopoietic cells, little study has been done on the effects of SHIP2 
inhibition, or more intriguingly, pan-SHIP inhibition. While we are not the first to 
identify pan-SHIP inhibitors, to the best of our knowledge, we are the first to 
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propose pan-SHIP inhibition as a novel therapeutic approach in the treatment of 
both hematopoietic and breast cancers. 
 In this study, we sought to expand upon work done previously in the lab 
demonstrating the ability of 3 α-aminocholestane to reduce the viability of 
multiple myeloma cells in vitro and in vivo. Via high throughput screening 
methods, it was our goal to identify compounds capable of inhibiting both SHIP1 
and SHIP2 simultaneously, hence affecting a broader range of malignancies. This 
screen yielded five lead pan-SHIP inhibitors, which we refer to as K118, K141, 
K142, K149, and K179. Throughout the course of this study, we have 
demonstrated the ability of these pan-SHIP inhibitors to prevent the hydrolysis of 
PtdIns(3,4,5)P3 to PtdIns(3,4)P2 in vitro, as well as to effectively reduce the 
viability of leukemia, multiple myeloma, and breast cancers ex vivo. In vivo 
studies are currently under way as described, but according to the preliminary 
data we are obtaining, several of the lead pan-SHIP inhibitors appear to be both 
well-tolerated by the host and effective at killing the multiple myeloma 
malignancies with which the mice have been challenged.  
In conclusion, findings of this study suggest that the inhibition of SHIP1 
and SHIP2 provides a feasible technique for targeting and killing cancer cells of 
various origins. While development of inhibitory compounds is still in 
preliminary phases, the potency of lead pan-SHIP inhibitors to kill breast and 
blood cancer cells has been clearly demonstrated. Our studies are currently being 
pursued and extended and will hopefully lead to clinical trials using enhanced 
derivatives of the most promising pan-SHIP inhibitors identified to date. Overall, 
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our findings suggest that the inhibition of SHIP1 and SHIP2, collectively, may 
provide a promising novel therapeutic approach in the treatment of both 
hematopoietic and non-hematopoietic cancers. We are beyond excited to see 
where these studies may lead us in the near future. 
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Figure 1. Enzymatic generation and hydrolysis of 
plasma membrane by lipid phosphatases. As one can see, PI3
phosphorylate PI(4,5)P
formation of PI(3,4,5)P3. Two classes of phosphatases can then ac
molecule in opposing ways. PTEN, a known tumor suppressor, dephosphorylates 
PIP3 at the 3’ position, returning PI(3,4,5)P3 to PI(4,5)P2. SHIP, on the other 
hand, dephosphorylates PIP3 at the 5’ position, resulting in the PI(3,4)P2 product. 
(INPP4 is negligible in the context of this study).
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Figure 2. Restriction map of pET
expression and purification process of human recombinant 
cDNA expression construct was amplifie
was subsequently inserted into the pET24b bacterial expression vector at the 
EcoR1 and Xho1 restriction sites (see top right).
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Figure 3A. Malachite Green standard curve measuring free phosphate in solution.  
The standard curve was generated using polynomial second order non
regression analysis. In simplest terms, the greater the level of free inorganic 
phosphate (in our study, liberat
 
 
 
B. Working stock calculation
Figure 3B. Calculation used to determine amount of solvent needed to 
10mM working stock of each inhibitory compound. This working stock was used 
in the Malachite Green Assay at a final concentration of 1mM. For dilution 
screens resulting in final concentrations 
stock was subsequently added to equal volume of pure solvent (i.e. 200
10µM stock + 200
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FIGURE 4. 
 
 
 
 
Figure 4. Relative enzymatic activity of recombinant SHIP1/2 protein with 
derivatives of parent
release) assays. Derivatives of aminosteroids (
quinolines (bottom center
Green assay and expressed as relative to solvent only control
parent compound is shown at leftmost position along x axis (i.e. 3AC, 
6PTQ). Only aminosteroid (3AC) and tryptamine (2P
notable pan-SHIP inhibition, and hence, were moved forward with in study. Of 
particular interest at the culmination of all Malachite screens were compounds 
K118, K141, K142, K149, and K179.
 
 
 
 
 
 
 
 compounds, as measured by Malachite Green (
top left), tryptamines (
) have been developed and tested in vitro by Malachite 
. In each graph, the 
IQ) derivatives showed 
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FIGURE 5. 
 
 
 
Fig. 5. Pan-SHIP 
myeloma and breast cancer cells
myeloma cells, (B)
with 3AC, 1PIE, 2PIQ or 6PTQ decre
manner. Consistent with it
in the latter two breast cancer cell lines 
hematopoietic compartment, do not express SHIP1.
 
 
 
 
 
 
inhibition reduces cell viability/induces cell death 
 ex vivo.  (A-C) Treatment of (A)
 MDA-MB-231 breast cancer or (C) MCF-7 breast cancer cells 
ased cell survival in a dose-
s selectivity for SHIP1, 3AC lacked any killing activity 
(B, C) which, as cancers outside of the 
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FIGURE 6. Lead aminosteroid panSHIP1/2 inhibitors vs. parent  
                            compound against leukemia and breast cancer cells 
 
 
Lead aminosteroid derivatives vs. parent against pediatric leukemia cells 
Lead aminosteroid derivatives vs. parent against adult leukemia cells 
Lead aminosteroid derivatives vs. parent against breast cancer cells 
FIGURE 7. 
 
8.  
 
 
Lead tryptamine, K149 vs. parent tryptamine K103 against pediatric leukemia cells
 
Lead tryptamine, K149 , vs. parent t
 
Lead tryptamine, K149, vs. parent tryptamine, K103, against breast cancer cells
ryptamine, K103, against adult leukemia cells
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Figure 8. Hemavet analysis of mice receiving 2PIQ treatment. According to 
blood samples taken from mice treated with 2PIQ at two different concentrations, 
we saw an increase in both neutrophils and myeloid derived suppressor cells 
(MDSCs) when compared to mice receiving vehicle treatment.  
 
FIGURE 9. 
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Figure 9. Vehicle vs. 3AC-treated NSG Mice, Week 3, Xenogen IVIS-200 
Optical In Vivo Imaging System. Based on luciferase bioluminescence, it is 
apparent that 3AC significantly reduces the viability of OPM2 multiple myeloma 
cells in vivo. (A) 100% of mice challenged with OPM2 cells and treated with 
vehicle only (0.3% Klucel) exhibit significant tumor growth. (B) Only 40% of 
mice challenged with OPM2 multiple myeloma cells then treated with 3AC have 
developed any visible tumor growth. Of the two mice in this image demonstrating 
tumorigenesis, one displays minimal tumor growth. 
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Figure 10. Treatment with 3AC results in significantly enhanced survival of mice 
post-multiple myeloma challenge. 3AC postponed the initial death event for the 
group receiving treatment to 10 weeks, while the vehicle group began to 
experience fatality at 7 weeks. More importantly, at the culmination of the 16-
week tumor challenge study, more than twice the number of 3AC-treated mice 
survived than did vehicle-treated mice. 
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Summary of Capstone Project 
 
The phosphotidylinositol 3-kinase, or PI3K, pathway is one of the most 
prominent cell proliferation and survival pathways in the human body. In a 
healthy model, activation and deactivation of this pathway is carefully regulated 
so as to allow for normal growth and the replacement of cells as needed. Upon 
deregulation (typically due to mutations) however, this signal transduction system 
can lead to the evasion of programmed cell death, the stimulation of a cell’s own 
growth, and the ability of a cell to replicate indefinitely. Given that one of the 
most fundamental definitions of cancer is an uncontrolled growth and 
proliferation of abnormal cells, it is not surprising that many tumor cells are 
observed to have hyperactivated PI3K signaling. 
Through meticulous study, it has been found that the phosphorylation of a 
regular cell membrane component, known as phosphatidylinositol(4,5) 
bisphosphate to phosphatidylinositol(3,4,5)trisphosphate (“PIP3”) activates this 
pathway, hence leading to increased cell growth and survival. For many years, it 
has been assumed that if phosphorylation turns the pathway “on”, then 
dephosphorylation ought to turn the pathway “off”.  Dephosphorylation of PIP3 
back to PIP2 is facilitated via two classes of lipid phosphatases: PTEN 
(phosphatase and tensin homolog) and SHIP (SH2-domain containing inositol 5’ 
phosphatase). PTEN has been very well-characterized and functions as a known 
tumor suppressor. By removing a phosphate group from the 3’ position of the 
inositol ring of PIP3, PTEN returns PIP3 to PIP2 in the “4,5” form (i.e. 
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phosphatidylinositol (3,4,5) trisphosphatephosphatidylinositol (4,5) 
bisphosphate). In doing so, PTEN prevents downstream components of the 
pathway (primarily the protein kinase, “Akt”) from binding to PIP3 and 
subsequently, signaling is discontinued. More recently discovered, the other class 
of phosphatase, SHIP, removes a phosphate group from the 5’ position of the 
inositol ring, hence returning PIP3 to PIP2 in the “3,4” form (i.e. 
phosphatidylinositol (3,4,5) trisphosphatephosphatidylinositol (3,4) 
bisphosphate). Unlike the “4,5” product, this “3,4” product actually seems to bind 
the downstream component Akt even more efficiently that does PIP3, and hence, 
enhances signaling leading to cell growth, proliferation, and survival. 
Because SHIP directly facilitates hyperactivation of the PI3K pathway, cancer 
biologists in the Kerr laboratory at SUNY Upstate Medical University are now 
looking for ways to inhibit its functioning. At this time, the molecular structure of 
SHIP has not been determined; therefore designing specific compounds to bind to 
and block the protein’s action is not a feasible option. Further challenging to the 
development of a specific and effective inhibitor is the fact that SHIP has two 
paralogs, or two copies of the gene that vary slightly. SHIP1 expression seems to 
be restricted to cells of the hematopoietic compartment (meaning those that form 
your blood and bone marrow cells), whereas SHIP2 seems to be ubiquitously 
expressed in cells throughout the body. Based on the properties of the SHIP 
molecule that are known, previous work in the Kerr lab identified a SHIP1-
selective inhibitor known as 3 α-aminocholestane (3AC), that proved capable of 
killing hematopoietic malignancies in mice. This inhibitor was far from perfect, 
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however. As mentioned, 3AC is SHIP1-selective, meaning that it does not target 
the other form of the protein, SHIP2, which in the compound’s presence is still 
able to hydrolyze PIP3PIP2. Given that SHIP1 expression is limited only to the 
hematopoietic domain, 3AC provides a feasible approach only in the treatment of 
blood cancers, and remains ineffective in the treatment of other non-
hematopoietic cancers (i.e. tissue cancers). Likewise, this compound is relatively 
insoluble; in order to work with 3AC in any in vitro or in vivo trials, it first must 
be dissolved in 100% ethanol at 100 °C, clearly not advantageous from a 
pharmacological perspective. Furthermore, during in vivo studies, 3AC was 
observed to confer slight toxicity to its hosts. 
Therefore, the goal of this study over the past two years has been to 
identify a new, more effective inhibitor that circumvents the challenges associated 
with 3AC. In close collaboration with Dr. John Chisholm’s organic chemistry lab 
at Syracuse University, who have synthesized more than 100 potential inhibitors, 
I have pursued a high throughput screening strategy to identify compounds with a 
higher solubility and lesser toxicity, capable of inhibiting the intracellular 
enzymatic activity of both SHIP1 and SHIP2. Through an in vitro technique 
known as the Malachite Green Assay, I was able to identify compounds that 
prevented SHIP1/2 from removing the phosphate group at the 5’ position of the 
PIP3 inositol ring. Upon completion of the Malachite screen on all compounds, 
those demonstrating the most significant inhibition were then carried into ex vivo 
trials. During this phase, compounds were introduced directly on to cell lines at 
varying concentrations to test their ability to reduce cell viability. Cell lines 
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studied included adult and pediatric leukemia, multiple myeloma, and breast 
cancer, allowing us to observe the effects of pan-SHIP inhibition on both 
hematopoietic and non-hematopoietic cancers. All of our lead pan-SHIP inhibitors 
demonstrated notable cell-killing activity against blood and breast malignancies. 
Lastly, the lead inhibitors identified through in vitro and ex vivo studies were then 
entered into in vivo trials. Compounds were initially administered at 
predetermined dosages to otherwise healthy mice in order to observe inherent 
toxic effects, if any. Upon completion of the toxicity screens, SCID (severe 
combined immunodeficient) mice were challenged with multiple myeloma cells, 
then subsequently treated with our panSHIP inhibitors. These mice are deficient 
in the T cells and B cells of the adaptive immune system, and therefore, if tumor 
growth is prevented or reduced, we know it is a direct result of the treatment they 
are receiving. This phase of the study is currently underway, but according to the 
preliminary data we are obtaining, several of the lead pan-SHIP inhibitors appear 
to be both well-tolerated by the host and effective at killing the malignancies with 
which the mice have been challenged. 
Findings of this study suggest that the inhibition of SHIP1 and SHIP2 
provides a feasible technique for targeting and killing cancer cells of various 
origins. While development of inhibitory compounds is still in preliminary 
phases, the potency of lead pan-SHIP inhibitors to kill breast and blood cancer 
cells has been clearly demonstrated. Our studies are currently being pursued and 
extended and will hopefully lead to clinical trials using enhanced derivatives of 
the lead pan-SHIP inhibitors identified to date. Overall, our findings suggest that 
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the inhibition of SHIP1 and SHIP2 may provide a promising novel therapeutic 
approach in the treatment of both hematopoietic and non-hematopoietic cancers, 
revolutionizing chemotherapy as it is currently known. 
 
  
 
